Sotrovimab for Injection

Sotrovimab is authorized for use under an Emergency Use Authorization (EUA) for treating mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (aged 12 years and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at increased risk for progression to severe COVID-19, including hospitalization or death.

Limitations of Use:

• Sotrovimab is not authorized for mild-to-moderate COVID-19 when the  infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information including variant susceptibility to these drugs and regional variant frequency.
• Sotrovimab is not authorized for patients who are hospitalized due to COVID-19, or require oxygen therapy and/or respiratory support due to COVID-19, or require an increase in baseline oxygen flow rate and/or respiratory support because of COVID-19 in those patients on chronic oxygen.

• Serious hypersensitivity reactions, including anaphylaxis, may occur with sotrovimab 500 mg/8 mL (62.5 mg/mL). If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis develop, promptly stop administration and start appropriate medicines and/or supportive care. 
• Infusion-related reactions, emerging during the infusion and up to 24 hours after the infusion, may occur with the use of sotrovimab. These reactions may be serious or life-threatening. If an infusion-related reaction occurs, slow or stop the infusion and administer appropriate medicines and/or supportive care. Monitor patients for at least 60 minutes after completion of the infusion for symptoms of hypersensitivity.  
• Clinical worsening of COVID-19 after the use of SARS-CoV-2 monoclonal antibody treatment may establish and may include symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (e.g., atrial fibrillation, bradycardia, tachycardia), fatigue, and altered mental status. Some of these events needed hospitalization.

What documents are required to import SOTROVIMAB to India?

SOTROVIMAB injection can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
• Import permit if applicable

Is SOTROVIMAB available in India?

SOTROVIMAB injection is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Sotrovimab in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

SOTROVIMAB can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of SOTROVIMAB (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Sotrovimab 500 mg/8 mL price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the SOTROVIMAB (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Sotrovimab®?

Sotrovimab is a Generic Name for the trade name drug Sotrovimab®.

What is the Manufacturer’s Name of Sotrovimab®?

Sotrovimab® is manufactured by GlaxoSmithKline LLC.

Is Sotrovimab® approved by the FDA?

Sotrovimab is not FDA-approved for any use. It received Emergency Use Authorization (EUA) from the US FDA on May 26, 2021.

What is the dosage and form of Sotrovimab® supplied?

Sotrovimab® is supplied as injections: 500 mg/8 mL (62.5 mg/mL) single-dose vial for intravenous use. 

What are the most common side effects of Sotrovimab®? 

The most common side effects of Sotrovimab® are diarrhea, rash, infusion-related reactions, and hypersensitivity adverse reactions. 

How much does Sotrovimab® cost in India?

The cost of Sotrovimab in India can vary. To procure this medication legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Sotrovimab®?

Store unopened vials of Sotrovimab refrigerated at 2 to 8°C (36 to 46°F) in the original carton. Do not freeze or shake. Protect from light.

Is it safe to buy Sotrovimab® online in India?

Yes, one can buy Sotrovimab online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can facilitate the supply of Sotrovimab through legal channels.